Significance and applications of nanoparticles in siRNA delivery for cancer therapy

Archive ouverte

Ali, Hafiz Muhammad | Urbinati, Giorgia | Raouane, Mouna | Massaad-Massade, Liliane

Edité par CCSD ; Informa Plc -

International audience. RNAi is a powerful gene silencing process that holds great promise in cancer therapy by the use of siRNA. The aim of this review is to give an outline on different approaches to deliver siRNA and to describe the advantages and disadvantages of these systems. The prospects for siRNA are to be substantially better than other therapies, as they are easily applicable to any therapeutic target. They also promise potent gene inhibition with exquisite selectivity, down to the level of a single nucleotide polymorphism, and can easily identify offending proteins or variants by screening across a gene sequence. The main obstacle of using RNAi technology in cancer treatment is to protect such a fragile and quickly metabolized biological molecule and to efficiently deliver it in vivo to the target cells. Therefore, there is a requirement for new systems, such as nanoparticles, for siRNA delivery to help the siRNAs reach, and improve their biodistribution in, target tissues.

Suggestions

Du même auteur

Effects of siRNA-squalene nanoparticles on RET/PTCs junction oncogenes in papillary thyroid carcinoma : from molecular and cellular studies to preclinical investigations. Effets des nanoparticules de siRNA-Squalène sur les oncogènes de jonction RET/PTCs dans le carcinome papillaire de la thyroïde : études moléculaires, cellulaires et investigations précliniques

Archive ouverte | Ali, Hafiz Muhammad | CCSD

Papillary thyroid carcinoma (PTC) is the most common of thyroid cancers. PTC is characterized by chromosomal rearrangements affecting chromosome 10 and leading to RET/PTC junction oncogenes. The most frequent ones are RET/PTC1 and...

Antineoplastic Effects of siRNA against TMPRSS2-ERG Junction Oncogene in Prostate Cancer

Archive ouverte | Urbinati, Giorgia | CCSD

International audience. TMPRSS2-ERG junction oncogene is present in more than 50% of patients with prostate cancer and its expression is frequently associated with poor prognosis. Our aim is to achieve gene knockdow...

Effects of siRNA on RET/PTC3 Junction Oncogene in Papillary Thyroid Carcinoma: From Molecular and Cellular Studies to Preclinical Investigations

Archive ouverte | Ali, Hafiz Muhammad | CCSD

International audience. RET/PTC3 junction oncogene is typical of radiation-induced childhood papillary thyroid carcinoma (PTC) with a short latency period. Since, RET/PTC3 is only present in the tumour cells, thus r...

Chargement des enrichissements...